Research programme: BACE-1 inhibitors - GlaxoSmithKlineAlternative Names: GSK 188909
Latest Information Update: 21 Apr 2011
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action BACE1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 31 Dec 2010 No development reported - Preclinical for Alzheimer's disease in United Kingdom (PO)